Ascendia

 

  MARKET NEWS

5 Prime Sciences Announces Strategic Collaboration With Lilly in Cardio-Metabolic Diseases
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer RNA Editing Program Targeting NTCP for Cholestatic Diseases
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
FDA Grants Orphan Drug Designation to Biompharma’s Microbiome-Modifying Biologic
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran for Treatment of Myotonic Dystrophy Type 1

  FEATURED EDITORIAL

  COMPANY PROFILE

Owen Mumford Pharmaceutical Services creates award-winning, patient-centric devices and its auto-injectors and pens are distributed around the world. With more than 70 years’ experience in medical devices, Owen Mumford has a global presence extending from manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany, and France. The Pharmaceutical Services division specialises in the design and manufacture of injectable drug delivery systems for the pharmaceutical, biotech, and generics industries. This includes auto-injectors and pens for subcutaneous and intramuscular administration. Pharmaceutical partners can choose between single and multi-dose, and reusable and disposable devices. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Arecor & Medtronic Diabetes Establish Collaboration to Develop Novel Thermostable Insulin for Implantable Pump Delivery

Arecor & Medtronic Diabetes Establish Collaboration to Develop Novel Thermostable Insulin for Implantable Pump Delivery

Medtronic to fund Arecor’s development of Arestat-enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination….

Akoya Biosciences & NeraCare Enter Exclusive Agreement to Enable Personalized Therapy Selection for Early Stage Melanoma Patients

Akoya Biosciences & NeraCare Enter Exclusive Agreement to Enable Personalized Therapy Selection for Early Stage Melanoma Patients

Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will…

Siren Biotechnology & Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

Siren Biotechnology & Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

Siren Biotechnology and Catalent Inc. recently entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene….

ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering First-in-Class Antiviral Innate Immunomodulator

ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering First-in-Class Antiviral Innate Immunomodulator

ENA Respiratory recently announced it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application US 18/112091 titled “Novel molecules” covering claims for….

  WHITEPAPERS & WEBINARS

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.

Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …

WHITE PAPER: Molly Modular Autoinjector Platform by SHL Medical

WHITE PAPER: Molly Modular Autoinjector Platform by SHL Medical

 

White Paper: A Systematic Review of Molly’s Integrated and Flexible Device Design and Development Model

SHL Medical has redefined the conventional platform model by adding modularity to its proven Molly® autoinjector technology. This white paper outlines SHL’s predictive response

…

New Opportunities for Oral Sustained Release Formulations With Polyvinyl Alcohol

New Opportunities for Oral Sustained Release Formulations With Polyvinyl Alcohol

 

Achieving the appropriate release kinetics for an active pharmaceutical ingredient (API) is essential to ensure success of the therapeutic. For example, for sustained release formulations, a consistent API dose over a prolonged period ensures that levels in the blood …

WHITEPAPER - Continuous Flow - An Emerging Alternative

WHITEPAPER - Continuous Flow - An Emerging Alternative

Pharmaceutical companies have traditionally been risk-averse, often adopting safe and well-established processes due to the conservative stance of regulatory agencies on novel methodologies. However, with the increasing complexity of drug molecules and the demand for newer and harsher reaction conditions, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 22 – Parenteral Contract Manufacturing
May 29 – Controlled Release